ALNY News and Press, Alnylam Pharmaceuticals Inc. From 06/28/21

Greenland Technologies (GTEC) -13% after prices $7.0M underwritten public offering of ordinary shares.Alnylam Pharmaceuticals (ALNY) -10%.Trevena (TRVN) -10% on addition to Russell 2000, Russell 3000, and Russell Microcap Indexes.Atossa Therapeutics (ATOS) -10%.Exelixis (EXEL)&...

Alnylam Pharmaceuticals (ALNY) announces that the FDA has accepted its New Drug Application ((NDA)) for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.The FDA has set PDUFA target actio...

– PDUFA Date Set for April 14, 2022 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for vutr...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 8 th annual series of “RNAi Roundtable” webinars over the coming weeks. The series will offer a range of presentations from Alnylam scient...

− Phase 3b Open-Label Study Showed Treatment with Patisiran Achieved Rapid and Sustained Reduction in Serum TTR Levels in hATTR Amyloidosis Patients with Polyneuropathy Progression Following Orthotopic Liver Transplant – − Additional Results from Pre-speci...

− APOLLO-B is the Industry’s Furthest Progressed Randomized, Double-Blind, Placebo-Controlled Pivotal Study of an Investigational TTR Silencer in Hereditary and Wild-type ATTR Amyloidosis with Cardiomyopathy − − Topline Results Expected in Mid-2022 ...

Alnylam has posted improving sales figures for Onpattro and positive pivotal data from the HELIOS-A study, but the hATTR program needs positive outcomes from ongoing cardiomyopathy studies in 2022/23. This year may be light on thesis-changing data, as most of the bigger data outcomes ...

− Initiates Clinical Study of Biannual Dosing Regimen of Investigational Vutrisiran in hATTR Patients with Polyneuropathy, with Data Expected in 2022 Potentially Supporting sNDA Submission – − Introduces New ATTR Program Aimed at Achieving Annual Dosing Re...

Dicerna approached doubling from its 52-week low, then drifted lower recently. Cash was raised recently from a royalty deal; has a runway to 2024. The platform and pipeline remain poised for long-term value. For further details see: Dicerna A Buy On Long-Term Potential ...

Alnylam Pharmaceuticals (ALNY) announces positive early results from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). Among 24 patients in ILLUMINATE-A who had been treated with lumasiran for 12 months, 46% (11/...